LONDON ONCOLOGY CLINICAL TRIALS OESOPHAGEAL CANCER STUDIES

Disease Area Treatment Phase Study Type Short Name Name of Study NIHR adopted? UKCRN ID Chief Investigator Trust Hospital Principle Investigator Contact Inclusion/Exclusion

King's College Hospital Chemoprevention of premalignant intestinal King's College Hospital NHS Foundation Trust neoplasia (ChOPIN) incorporating inherited Princess Royal Hospital http://www.cancerresearchuk.o predisposition of neoplasia (IPOD) analysis of rg/about-cancer/trials/a-study- Royal Marsden Hospital NHS Prevention NA Interventional ChOPIN genomic DNA from AspECT and BOSS clinical trials. It Yes 6858 Prof Janusz Jankowski Royal Marsden Hospital Prof David Cunningham [email protected] to-find-out-why-certain-people- Foundation Trust also incorporates patients undergoing genomic develop-oesophageal-cancer- assessment independent of the AspECT and BOSS Queen Elizabeth Woolwich chopin Lewisham and Greenwich NHS Trust trials. University Hospital Lewisham North West London Hospitals NHS http://www.cancerresearchuk.o Evaluation of a St Mark's Hospital NonEndoscopic Device Evaluation of a Non-Endoscopic Immunocytological Trust rg/about-cancer/trials/a-study- NA Interventional Device (Cytosponge) for Barrett's Esophagus Yes 9461 Dr Rebecca Fitzgerald to-see-how-well-a-new-way- for Barrett's Screening in a Case-Control Study University College London Hospitals University College London screening-for-barretts- [email protected] Screening Barrett's Oesophagus - BEST 2 NHS Foundation Trust Hospital oesophagus-works-best2 Oesophagus Multiparametric MRI Multiparametric Magnetic Resonance Imaging for Guy's and St Thomas' NHS Foundation NA Interventional Yes 15993 Dr Vicky Goh Guy's Hospital Dr Vicky Goh [email protected] for Oesophageal Cancer Oesophageal cancer assessment:a pilot study Trust (MIMOSA) https://ukctg.nihr.ac.uk/trials/tri University College London Hospitals University College London al-details/trial- Prof Laurence Lovat [email protected] Barrett's oesophagus and optical biopsy using elastic NHS Foundation Trust Hospital details?trialNumber=ISRCTN582 Screening NA Observational BOOST scattering spectroscopy to target high risk lesions Yes 4363 Dr Sarah Jevons 35785 (BOOST) Royal Free London NHS Foundation Royal Free Hospital Trust Guy's and St Thomas' NHS Foundation St Thomas' Hospital Dr Jason Dunn [email protected] http://www.barretts- A National Registry for HALO360 and HALO90 Trust oesophagus.co.uk/patients_UK_ Treatment NA Interventional Radiofrequency Ablation of Barretts Columnar Lined No Prof Laurence Lovat UK HALO Registry Imperial College NHS Healthcare Trust St Mary's Hospital Dr Jonathan Hoare [email protected] National_HALO_patient_registry Oesophagus University College London Hospitals University College London .htm Prof Laurence Lovat [email protected] NHS Foundation Trust Hospital

St Mary's Hospital Prof George Hanna [email protected] http://public- Patients odp.nihr.ac.uk/QvAJAXZfc/open NHS BRENT CCG referred for a Non-invasive diagnostic doc.htm?document=CRNCC_Use GI endoscopy Non-invasive testing for the diagnosis and rs%2FFind%20A%20Clinical%20R Screening NA Observational Yes 18063 Prof George Hanna Imperial College NHS Healthcare Trust NHS EALING CCG or undering GI testing for Gastro- assessment of Gastro-intestinal disease esearch%20Study.qvw&sheet=S resection for intestinal disease NHS HAMMERSMITH AND H75&bookmark=Document\BM cancer FULHAM CCG 02&select=LB572,=StudyID=205 45 NHS HILLINGDON CCG

A randomised Phase II study of two preoperative NeoSCOPE: Neoadjuvant - chemoradiotherapy regimes (oxaliplatin and North West London Hospitals NHS Neoadjuvant II Interventional Study of Chemoradiotherapy in capecitabine followed by radiotherapy with either Yes 13764 Dr Tom Crosby St Mark's Hospital Trust OesoPhagEal Cancer oxaliplatin and capecitabine or paclitaxel and carboplatin) for resectable oesophageal cancer.

The Management of Preoperative Iron Deficiency Preoperative Iron Deficiency & Preoperative and Anaemia in Patients with Oesophagogastric Guy's and St Thomas' NHS Foundation NA Observational Anaemia in Oesophagogastric Yes 18908 Mr James Gossage St Thomas' Hospital Ms Orla Hynes [email protected] Cohort Study cancer, undergoing the Curative Surgical Treatment Trust Cancer Pathway: A Prospective Observational Cohort Study.

Prehabilitation in patients with oEsophgeal Guy's and St Thomas' NHS Foundation Pilot Interventional No Mr James Gossage St Thomas' Hospital [email protected] Pre-EMPT Malignancies undergoing Peri-operative Treatment Trust

Health-related Quality of Life after Surgery for Guy's and St Thomas' NHS Foundation NA Observational HRQL after Upper GI Surgery Yes 14702 Prof Jesper Lagergren Prof Jesper Lagergren [email protected] Upper Gastrointestinal Tumours Trust

Imperial College NHS Healthcare Trust St Mary's Hospital Prof George Hanna [email protected] Pre-Surgical Oesophageal Cancer Clinical and Molecular http://www.cancerresearchuk.o Stratification Study (OCCAMS) - A Multicentre Study Guy's and St Thomas' NHS Foundation St Thomas' Hospital [email protected] rg/about-cancer/trials/a-study- to Determine Predictive and Prognostic Biomarkers Trust IV Observational Yes 8880 Dr Rebecca Fitzgerald looking-cell-changes-pre-cancer- OCCAMS and Therapeutic Targets for Oesophageal and Barking, Havering and Redbridge and-cancer-where-food-pipe- Junctional Adenocarcinoma including Whole University Hospitals NHS Trust meets-stomach-occams Genome Sequencing University College London Hospitals University College London [email protected] NHS Foundation Trust Hospital Patient Experience of Patient Experience of Swallowing Following The Royal Marsden NHS Foundation post-surgical NA Observational Swallowing Following No Dr Theresa Wiseman Royal Marsden Hospital Dr Theresa Wiseman [email protected] Oeosphageal Surgery Trust Oeosphageal Surgery Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (MAGIC regimen) vs. https://clinicaltrials.gov/ct2/sho 1st line III Interventional neoadjuvant chemoradiation (CROSS protocol) in Yes 18094 Mr Shaun Preston Imperial College NHS Healthcare Trust St Mary's Hospital Prof George Hanna [email protected] Neo-AEGIS w/NCT01726452 adenocarcinoma of the oesophagus and oesophago- gastric junction.

The Royal Marsden NHS Foundation Royal Marsden Hospital Dr Ian Chau A Randomized, Multicenter, Double Blind, Phase III Trust Study of Adjuvant Nivolumab or Placebo in Subjects https://clinicaltrials.gov/ct2/sho Adjuvant III Interventional No Dr Ian Chau CheckMate 577 With Resected Esophageal, or Gastroesophageal Guy's and St Thomas' NHS Foundation w/NCT02743494 Guy's Hospital Junction Cancer Trust

Please contact [email protected] to update Page 1 of 5 APRIL 2017 LONDON ONCOLOGY CLINICAL TRIALS OESOPHAGEAL CANCER STUDIES

Disease Area Treatment Phase Study Type Short Name Name of Study NIHR adopted? UKCRN ID Chief Investigator Trust Hospital Principle Investigator Contact Inclusion/Exclusion Univeristy College London University College London Hospital Hospital A Phase 3 Randomized, Double-Blind, Placebo- The Royal Marsden NHS Foundation https://clinicaltrials.gov/ct2/sho III Royal Marsden Hospital Prof David Cunningham [email protected] Controlled Study to Evaluate the Efficacy and Safety Trust w/NCT02545504 Interventional GAMMA-1 of GS-5745 Combined With mFOLFOX6 as First Line Yes 27513 Prof David Cunningham Treatment in Patients With Advanced Gastric or University College London Hospitals Univeristy College London [email protected] Gastroesophageal Junction Adenocarcinoma NHS Foundation Trust Hospital Guy's and St Thomas' NHS Foundation http://www.cancerresearchuk.o A Phase I/IIa trial of AZD4547 in combination with Guy's Hospital [email protected] rg/about-cancer/trials/a-trial-of- I/II Interventional FACING Yes 11668 Prof T R J Evans Trust Cisplatin and Capecitabine (CX) Imperial College NHS Healthcare Trust St Mary's Hospital [email protected] azd4547-with-cisplatin-and- capecitabine-for-advanced- Guy's and St Thomas' NHS Foundation Guy's Hospital Dr Nick Maisey [email protected] Trust Advanced 1st line https://ukctg.nihr.ac.uk/trials/tri Alternative chemotherapy for frail or elderly Imperial College NHS Healthcare Trust St Mary's Hospital Dr Danielle Power [email protected] al-details/trial- III Interventional patients with advanced gastric or oesophageal Yes 15037 Prof Matt Seymour Oesophageal G02 Barking, Havering and Redbridge details?trialNumber=ISRCTN446 cancer cancer University Hospitals NHS Trust 87907 Bart's Health NHS Trust St Bartholomew's Hospital A Phase 3, Multicenter, Randomized, Double-Blind, Royal Marsden Hospital NHS NCRN366: Rilotumumab + ECX Placebo Controlled Study of Rilotumumab (AMG Royal Marsden Hospital Prof David Cunningham [email protected] Foundation Trust in 1st line c-Met Gastric or 102) with Epirubicin, Cisplatin, and Capecitabine https://clinicaltrials.gov/ct2/sho III Interventional Yes 12906 Prof David Cunningham Gastroesophageal Junction (ECX) as First-line Therapy in c-Met Enriched w/NCT01697072 Guy's and St Thomas' NHS Foundation Adenocarcinoma Advanced Gastric or Gastroesophageal Junction Dr Nick Maisey [email protected] Trust Adenocarcinoma

Please contact [email protected] to update Page 2 of 5 APRIL 2017 LONDON ONCOLOGY CLINICAL TRIALS OESOPHAGEAL CANCER STUDIES

Disease Area Treatment Phase Study Type Short Name Name of Study NIHR adopted? UKCRN ID Chief Investigator Trust Hospital Principle Investigator Contact Inclusion/Exclusion Royal Marsden Hospital NHS Royal Marsden Hospital Prof David Cunningham [email protected] Foundation Trust Royal Free London NHS Foundation Planning treatment for oesophago-gastric cancer: a Royal Free Hospital Trust https://clinicaltrials.gov/ct2/sho III Interventional randomised maintenance therapy trial (PLATFORM Yes 18432 Prof David Cunningham PLATFORM Guy's and St Thomas' NHS Foundation w/NCT02678182 Trial) Dr Nick Maisey [email protected] Trust Princess Alexandra Hospital NHS Trust Princess Alexandra Hospital 1st line Maintenance A Phase III Open-label, Multicenter Trial of Maintenance Therapy With Avelumab Barts Health NHS Trust St Bartholomew's Hospital Dr David Propper [email protected] (MSB0010718C) Versus Continuation of First-line https://clinicaltrials.gov/ct2/sho III Interventional No JAVELIN Gastric 100 Chemotherapy in Subjects With Unresectable, w/NCT02625610 Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro-esophageal Junction University College London Hospitals University College London Kai-Keen Shiu [email protected] NHS Foundation Trust Hospital A Phase III Randomized, Double-Blind, Placebo- NCRN - 3258 BBI608 plus Controlled Clinical Trial of BBI608 plus Weekly https://clinicaltrials.gov/ct2/sho Weekly Paclitaxel in Gastric Royal Marsden Hospital NHS III Interventional Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Yes 18109 Dr Naureen Starling Royal Marsden Hospital Dr Naureen Starling [email protected] w/study/NCT02178956?show_lo and GEJ Adenocarcinoma Foundation Trust Patients with Advanced, Previously Treated Gastric cs=Y#locn (216525) and Gastro-Esophageal Junction Adenocarcinoma

2nd line Royal Marsden Hospital NHS A Phase 2, Open-Label, Randomized Study to Royal Marsden Hospital Prof David Cunningham [email protected] Foundation Trust Evaluate the Efficacy and Safety of GS-5745 https://clinicaltrials.gov/show/N II Interventional Combined With Nivolumab Versus Nivolumab Alone Yes 31219 Dr Richard Hubner GS-5745 CT02864381 in Subjects With Unresectable or Recurrent Gastric University College London Hospitals University College London or Gastroesophageal Junction Adenocarcinoma [email protected] NHS Foundation Trust Hospital [email protected] Barts Health NHS Trust St Bartholomew’s Hospital Prof David Propper [email protected] A phase II Study of Pembrolizumab Monotherapy in Third-Line Previously Treated Subjects with KEYNOTE - 180 / Advanced/ Metastatic Adenocarcinoma or University College London Hospitals University College London Advanced 3rd line II Interventional Yes [email protected] CANC 5428 Squamous Cell Carcinoma of the Esophagus or NHS Foundation Trust Hospital Advanced / Metastatic Siewert Type I Adenocarcinoma of the Esophaghogastric Junction Basildon and Thurrock University Palliative Radiotherapy in Addition to Self-expanding Hospital NHS Foundation Trust Advanced - Metal Stent for Improving Dysphagia and Survival in Southend University Hospital NHS https://clinicaltrials.gov/ct2/sho III Interventional Yes 14309 Dr Douglas Adamson Supportive Care ROCS Study Advanced Oesophageal Cancer: ROCS (Radiotherapy Foundation Trust w/NCT01915693 After Oesophageal Cancer Stenting) Study. Imperial College Healthcare NHS Trust St Mary's Hospital [email protected]

Guy's and St Thomas' NHS Foundation Guy's Hospital Dr Nick Maisey [email protected] Trust Royal Marsden Hospital NHS Royal Marsden Hospital Prof David Cunningham [email protected] Foundation Trust A Randomised Phase II/III trial of Peri-operative Royal Free London NHS Foundation Chemotherapy with or without Bevacizumab in Trust Operable Oesophagogastric Adenocarcinoma and St George's University Hospitals NHS St George's University https://clinicaltrials.gov/ct2/sho 1st line II/III Interventional Yes 1752 Prof David Cunningham ST03 (in selected centres) A Feasibility Study Evaluating Foundation Trust Hospital w/NCT00450203 Lapatinib in HER-2 Positive Oesophagogastric Bart's Health NHS Trust St Bartholemew's Hospital Dr Sarah Slater Adenocarcinomas. Barking, Havering and Redbridge Queen's Hospital Dr Sherif Raouf University Hospitals NHS Trust Imperial College NHS Healthcare Trust St Mary's Hospital Dr Danielle Power [email protected] Her2+ A randomized, multicenter, adaptive phase II-III study to evaluate the efficacy and safety of http://www.cancerresearchuk.o NCRN369: GATSBY TDM1 vs trastuzumb emtansine (T-DM1) versus taxane rg/about-cancer/trials/a-trial- Advanced 2nd II/III Interventional taxane in previously treated (docetaxel or paclitaxel) in patients with previously Yes 12204 Dr Was Mansoor Imperial College NHS Healthcare Trust looking-at-tdm1-for-advanced- line advanced HER2+ gastric ca treated locally advanced or metastatic HER2- her2-positive-cancer-of-the- positive gastric cancer, including adenocarcinoma of stomach-or-goj-cancer the gastroesophageal junction Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With Advanced 2nd HER2 Positive Carcinomas of the Distal Esophagus, Royal Marsden Hospital NHS https://clinicaltrials.gov/ct2/sho II Interventional IMPACT - MM-111 No Dr David Watkins Royal Marsden Hospital Dr David Watkins line Gastroesophageal (GE) Junction and Stomach Who Foundation Trust w/NCT01774851 Have Failed Front Line Metastatic or Locally Advanced Therapy Guy's and St Thomas' NHS Foundation [email protected] A Multicenter, Phase 2, Single Arm, Two Cohort Trust http://www.cancerresearchuk.o NCRN - 2265 MET Amplified Study Evaluating the Efficacy, Safety, and rg/about-cancer/trials/a-trial-of- Advanced 2nd Gastric/Gastroesophageal Pharmacokinetics of AMG 337 in Subjects with MET Royal Marsden Hospital NHS amg337-for-advanced-solid- MET+ II Interventional Yes 15315 Dr Anne Thomas Royal Marsden Hospital Prof David Cunningham [email protected] line Junction/Esophageal Amplified Gastric/Gastroesophageal Foundation Trust tumours-that-have-large- Adenocarcinoma Junction/Esophageal Adenocarcinoma or Other MET number-of-copies-of-gene-

Please contact [email protected] to update Page 3 of 5 APRIL 2017 LONDON ONCOLOGY CLINICAL TRIALS OESOPHAGEAL CANCER STUDIES

Disease Area Treatment Phase Study Type AdenocarcinomaShort Name Junction/EsophagealName Adenocarcinoma of Study or Other MET NIHR adopted? UKCRN ID Chief Investigator Trust Hospital Principle Investigator Contact number-of-copies-of-gene-Inclusion/Exclusion Mount Vernon Cancer Amplified Solid Tumors East and North Hertfordshire NHS Trust [email protected] called-met Centre c-MYC and Proof-of-concept Study of Ibrutinib in c-MYC and The Royal Marsden NHS Foundation https://clinicaltrials.gov/ct2/sho HER2 2nd line+ II Interventional No Dr Ian Chau Royal Marsden Hospital Dr Ian Chau [email protected] iMYC HER2 Amplified Oesophagogastric Carcinoma (iMYC) Trust w/NCT02884453 amplified

FGFR1/2 Amplified Proof-of-Concept Study Royal Marsden Hospital NHS Royal Marsden Hospital Prof David Cunningham [email protected] https://clinicaltrials.gov/ct2/sho Gastric, of AZD4547 in Patients Proof-of-Concept Study of AZD4547 in Patients With Foundation Trust Advanced II Interventional No Prof David Cunningham w/NCT01795768?term=azd4547 oesophageal, FGFR1 or FGFR2 Amplified Tumours With FGFR1 or FGFR2 &rank=7 breast or SCC Amplified Tumours of lung cancer Guy's and St Thomas' NHS Foundation Guy's Hospital Dr Nick Maisey [email protected] Trust http://www.cancerresearchuk.o CheckMate032: A Phase 1/2, Open-label Study of NCRN - 2808 CheckMate032 rg/about-cancer/trials/a-trial- Nivolumab Monotherapy or Nivolumab combined Royal Marsden Hospital NHS I/II Interventional Nivolumab combined with Yes 15842 Prof Jeff Evans Royal Marsden Hospital Dr Ian Chau [email protected] nivolumab-ipilimumab-people- with Ipilimumab in Subjects with Advanced or Foundation Trust Ipilimumab in Solid Tumours with-solid-tumours-that-have- Metastatic Solid Tumors spread A Phase 1/2 Study to Evaluate the Safety, NCRN - 2888 MEDI4736 in Royal Marsden Hospital NHS I/II Interventional Tolerability, and Pharmacokinetics of MEDI4736 in Yes 15886 Prof David Cunningham Royal Marsden Hospital Prof David Cunningham [email protected] Advanced Solid Tumors Foundation Trust Subjects With Advanced Solid Tumors A Phase 1b, Open-Label, Dose Escalation and Expansion Study of Demcizumab Plus Royal Marsden Hospital NHS https://clinicaltrials.gov/ct2/sho Solid Tumours Advanced Ib Interventional No Dr. Juanita S Lopez Royal Marsden Hospital Dr. Juanita S Lopez [email protected] CANC 5088 Pembrolizumab in Patients With Locally Advanced or Foundation Trust w/NCT02722954 Metastatic Solid Tumors Barts Health NHS Trust St Bartholomew's Hospital University College London Hospitals University College London A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) Dr Rebecca Kristeleit [email protected] CANC 5659 NHS Foundation Trust Hospital https://clinicaltrials.gov/ct2/sho I Interventional in Combination with Tremelimumab (Anti-CTLA- No Royal Free London NHS Foundation w/NCT02261220 (REFMAL 444) 4Antibody) in Subjects with Advanced Solid Tumors Royal Free Hospital Trust Sarah Cannon Research Institute UK SCRI Referral Template

Please contact [email protected] to update Page 4 of 5 APRIL 2017 LONDON ONCOLOGY CLINICAL TRIALS OESOPHAGEAL CANCER STUDIES

Disease Area Treatment Phase Study Type Short Name Name of Study NIHR adopted? UKCRN ID Chief Investigator Trust Hospital Principle Investigator Contact Inclusion/Exclusion Royal Marsden Hospital NHS Royal Marsden Hospital Dr Ravishankar Raobaikady [email protected] Foundation Trust

Hillingdon Hospitals NHS Foundation Hillingdon Hospital Dr Cheryl Messer Trust

Bart's Health NHS Trust Royal London Hospital Dr Shubha Allard [email protected]

Royal Free London NHS Foundation Pateints with Royal Free Hospital Dr Susan Mallett A randomised double-blind controlled phase III anaemia Trust study to compare the efficacy and safety of undergoing Supportive Care III Interventional intravenous ferric carboxymaltose with placebo in Yes 13680 Dr Toby Richards major open PREVENTT King's College Hopsital King's College Hopsital Dr Tim Hughes patients with anaemia undergoing major open https://clinicaltrials.gov/ct2/sho abdominal abdominal surgery University College London Hospitals University College London w/NCT01692418 surgery Dr Khaled Dawas [email protected] NHS Foundation Trust Hospital

Imperial College Healthcare NHS Trust St Mary's Hospital Dr Asela Dharmadasa [email protected]

Imperial College Healthcare NHS Trust Charing Cross Hospital Dr Asela Dharmadasa [email protected]

Guy's and St Thomas' NHS Foundation Guy's Hospital Dr Jugdeep Dhesi [email protected] Trust

Charing Cross Hospital [email protected]

Hammersmith.Cancertrials@imperial. Hammersmith Hospital Imperial College Healthcare NHS Trust Dr Danielle Power nhs.uk

St Mary's Hospital London [email protected] http://www.cancerresearchuk.o rg/about-cancer/find-a-clinical- Venous Select-d: Anticoagulation Therapy in SELECTeD Chelsea & Westminster Hospital NHS Chelsea & Westminster trial/a-study-comparing-blood- Dr Tom Newsom-Davis Thromboemb Supportive Care III Interventional Select-D Cancer Patients at Risk of Recurrence of Venous Yes 14296 Prof Annie Young Foundation Trust Hospital thinning-injection-with-blood- olism Thromboembolism thinning-tablet-for-people-with- London North West Hospital NHS Trust Ealing Hospital Dr Conrad Lewanski cancer-who-have-blood-clot- The Hillingdon Hospitals NHS select-d Hillingdon Hospital Dr Amy Guppy Foundation Trust The Royal Marsden NHS Foundation Royal Marsden Hospital Dr Ian Chau [email protected] Trust Mount Vernon Cancer East and North Hertfordshire NHS Trust [email protected] Centre Cancer and Venous Access (CAVA) - A randomised All cancers Delivery of Cancer And Venous controlled trial with associated qualitative research Hammersmith.Cancertrials@imperial. http://www.isrctn.com/ISRCTN4 receiving III Interventional Yes 14600 Prof Jon Moss Imperial College Healthcare NHS Trust Hammersmith Hospital Dr Alison Graham treatment of venous access devices for the delivery of long- nhs.uk 4504648 chemo Access (CAVA) term chemotherapy Patients who have PROGRess : Identifying Prognostic and PRedictive undergone Biomarkers in Oesophagogastric Cancer : Royal Marsden Hospital NHS Pilot NA Observational Yes 19210 Prof David Cunningham Royal Marsden Hospital Prof David Cunningham [email protected] surgery for PROGRess GSTT/Royal Marsden translational research Foundation Trust Oesophagoga collaboration stric Cancer Determination of the Role of Microarray for Prognosis and Prediction to Chemotherapy Royal Marsden Hospital NHS https://clinicaltrials.gov/ct2/sho Oesophageal Pilot NA Observational No Prof David Cunningham Royal Marsden Hospital Prof David Cunningham [email protected] Microarray Sensitivity in Patients With Operable, Locally Foundation Trust w/NCT00220077 Advanced and Metastatic Oesophageal Cancer Royal Free London NHS Foundation http://public- Pilot NA Royal Free Hospital Prof Tim Meyer [email protected] Systematic Evaluation of the Immune Environment Trust odp.nihr.ac.uk/QvAJAXZfc/open Observational Yes 20545 Prof Tim Meyer IMMUNET of Neuroendocrine Tumours doc.htm?document=CRNCC_Use Pilot NA King's College London King's College London rs%2FFind%20A%20Clinical%20R http://public- Neuroendocri odp.nihr.ac.uk/QvAJAXZfc/open ne tumours Characterisation of doc.htm?document=CRNCC_Use Characterisation of circulating tumour cells and Royal Free London NHS Foundation rs%2FFind%20A%20Clinical%20R Pilot NA Observational Yes 14929 Prof Tim Meyer Royal Free Hospital Prof Tim Meyer CTCs and cDNA in cDNA in patients with cancer Trust esearch%20Study.qvw&sheet=S patients with cancer H75&bookmark=Document\BM 02&select=LB572,=StudyID=205 45

Please contact [email protected] to update Page 5 of 5 APRIL 2017